ArticleNature communications2026

Dalpiciclib plus chidamide in HR + /HER2-advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial.

Jinmei Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.